High dose chemotherapy with stem cell support in the treatment of testicular cancer

Table 4 High dose chemotherapy for third or subsequent lines, refractory/absolute refractory

Ref.	Type of study	Number of patients	Setting	Protocol	OS (%)	PFS (%)	Medianfollow-up (mo)
Vaena et al[38]	Retrospective	80	Second and subsequent lines, refractory	HD-CE × 2	40 (2 yr)	32 (2 yr)	24
Lotz et al[39]	Prospective	45	Second and subsequent lines, refractory/absolute refractory	Epi-Tax × 2 + HD Thio-Tax × 1 + HD-ICE × 2	23.5 (3 yr)	23.5 (3 yr)	36
Kondagunta et al[40]	Prospective	47	Second and third line, refractory/absolute refractory	TI × 2 + HD-CE × 3	NR	51	40
Einhorn et al[31]	Retrospective	49	Third or subsequent	HD-CE × 2	55	45	48
Lorch et al[41]	Retrospective	49	Third or subsequent, refractory	Various	17 (5 yr)	26 (5 yr)	48
Popovic et al[42]	Prospective	8	Forth or fifht line, refractory	Epi-Tax × 2-3 + HD-CE × 1-2	Median 11 mo	NR	NR

Epi-Tax: Epirubicine, paclitaxel; HD: High dose; HD-CE: High dose carboplatin, etoposide; HDCT: High dose chemotherapy; HD-ICE: High dose ifosfamide, carboplatin, etoposide; NR: Not reported; OS: Overall survival; PFS: Progression free survival; SDCT: Standard-dose chemotherapy; Thio-Tax: Thiotepa, paclitaxel; TI: Paclitexel, ifosfamide.